KRYSTAL BIOTECH INC.

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

06 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

05 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

26 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

15 May 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

08 May 2024 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

06 May 2024 08:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

26 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

04 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

19 Dec 2023 07:00:00 By Nasdaq GlobeNewswire